These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 9433640)

  • 1. Cost-effectiveness of screening for common cancers.
    Wagner JL
    Cancer Metastasis Rev; 1997; 16(3-4):281-94. PubMed ID: 9433640
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of screening for cancer in the Nordic countries on deaths, cost and quality of life up to the year 2017.
    Hristova L; Hakama M
    Acta Oncol; 1997; 36 Suppl 9():1-60. PubMed ID: 9143316
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preventing cancer: using health dollars wisely.
    Wasserman S
    NCSL Legisbrief; 2004 Feb; 12(8):1-2. PubMed ID: 14974484
    [No Abstract]   [Full Text] [Related]  

  • 4. Cost-effectiveness analyses of colorectal cancer screening: a systematic review for the U.S. Preventive Services Task Force.
    Pignone M; Saha S; Hoerger T; Mandelblatt J
    Ann Intern Med; 2002 Jul; 137(2):96-104. PubMed ID: 12118964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Screening, prevention and treatment of cervical cancer -- a global and regional generalized cost-effectiveness analysis.
    Ginsberg GM; Edejer TT; Lauer JA; Sepulveda C
    Vaccine; 2009 Oct; 27(43):6060-79. PubMed ID: 19647813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Economic evaluation of population-based mass screening for the early detection of cancer: a systematic review].
    Muszbek N; Koncz T; V Hajdú P; Adány R
    Magy Onkol; 2002; 46(2):119-29. PubMed ID: 12202891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of cervical-cancer screening in five developing countries.
    Goldie SJ; Gaffikin L; Goldhaber-Fiebert JD; Gordillo-Tobar A; Levin C; Mahé C; Wright TC;
    N Engl J Med; 2005 Nov; 353(20):2158-68. PubMed ID: 16291985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The cost-effectiveness of HPV vaccination in addition to screening: a Dutch perspective.
    Setiawan D; Luttjeboer J; Westra TA; Wilschut JC; Suwantika AA; Daemen T; Atthobari J; Wilffert B; Postma MJ
    Expert Rev Vaccines; 2015 Apr; 14(4):589-604. PubMed ID: 25482311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Costs and cost-effectiveness of colorectal cancer prevention and therapy.
    Schrag D; Weeks J
    Semin Oncol; 1999 Oct; 26(5):561-8. PubMed ID: 10528905
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of the conventional papanicolaou test with a new adjunct to cytological screening for squamous cell carcinoma of the uterine cervix and its precursors.
    Taylor LA; Sorensen SV; Ray NF; Halpern MT; Harper DM
    Arch Fam Med; 2000 Aug; 9(8):713-21. PubMed ID: 10927709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evolution of multiple disease screening in Keelung: a model for community involvement in health interventions?
    Wang PE; Wang TT; Chiu YH; Yen AM; Chen TH
    J Med Screen; 2006; 13 Suppl 1():S54-8. PubMed ID: 17227644
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of colonoscopy in screening for colorectal cancer.
    Sonnenberg A; Delcò F; Inadomi JM
    Ann Intern Med; 2000 Oct; 133(8):573-84. PubMed ID: 11033584
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of Human Papilloma Virus (HPV) vaccination in Nigeria: a decision analysis using pragmatic parameter estimates for cost and programme coverage.
    Ekwunife OI; Lhachimi SK
    BMC Health Serv Res; 2017 Dec; 17(1):815. PubMed ID: 29216880
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness analysis of adding a quadrivalent HPV vaccine to the cervical cancer screening programme in Switzerland.
    Szucs TD; Largeron N; Dedes KJ; Rafia R; Bénard S
    Curr Med Res Opin; 2008 May; 24(5):1473-83. PubMed ID: 18413014
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of costs and benefits of advances in cytologic technology. International Academy of Cytology Task Force summary. Diagnostic Cytology Towards the 21st Century: An International Expert Conference and Tutorial.
    Melamed MR; Hutchinson ML; Kaufman EA; Schechter CB; Garner D; Kobler TP; Krieger PA; Reith A; Schenck U
    Acta Cytol; 1998; 42(1):69-75. PubMed ID: 9479325
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness analysis for Pap smear screening and human papillomavirus DNA testing and vaccination.
    Chen MK; Hung HF; Duffy S; Yen AM; Chen HH
    J Eval Clin Pract; 2011 Dec; 17(6):1050-8. PubMed ID: 21679279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness studies on cervical cancer.
    Brown AD; Raab SS; Suba EJ; Wright RG;
    Acta Cytol; 2001; 45(4):509-14. PubMed ID: 11480710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inefficiencies and High-Value Improvements in U.S. Cervical Cancer Screening Practice: A Cost-Effectiveness Analysis.
    Kim JJ; Campos NG; Sy S; Burger EA; Cuzick J; Castle PE; Hunt WC; Waxman A; Wheeler CM;
    Ann Intern Med; 2015 Oct; 163(8):589-97. PubMed ID: 26414147
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of cervical cancer screening and follow-up programs.
    Celentano DD; deLissovoy G
    Public Health Rev; 1989-1990; 17(2-3):173-240. PubMed ID: 2518819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is it cost effective to introduce screening programmes for colorectal cancer? Illustrating the principles of optimal resource allocation.
    Gyrd-Hansen D
    Health Policy; 1997 Sep; 41(3):189-99. PubMed ID: 10170088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.